Pipeline
Pipeline

Our Pipeline

An overview of the clinical studies on our own drug candidates and the most advanced clinical programs of our partners.

Our Pipeline

Latest Update: June 2022

MorphoSys' Clinical Programs

Compound / Brand name
Indication
NCT
Tafasitamab
Target CD19
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only – accelerated approval)
Diffuse large B-cell lymphoma (DLBCL) (frontMIND)
Relapsed or refractory follicular or marginal zone lymphoma (FL; MZL) (inMIND)
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (B-MIND)
Diffuse large B-cell lymphoma (DLBCL) (firstMIND)
Pelabresib
BET Inhibitor
Myelofibrosis (MANIFEST-2)
Myelofibrosis (MANIFEST)
CPI-0209
EZH2 Inhibitor
Advanced Solid Tumors / Hematologic Malignancies

Selection of our Partners’ Clinical Programs

Compound / Brand name
Partner
Program
Compound / Brand name
Gantenerumab
Partner
Roche
Program

Gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration. It is being studied by Roche in several Phase 3 trials for the treatment of people living with Alzheimer’s disease and prevention of Alzheimer’s. Gantenerumab received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA).

Compound / Brand name
Otilimab (GSK3196165)
Partner
GlaxoSmithKline
Program

Otilimab is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that is developed by GSK for the treatment of rheumatoid arthritis (Phase 3).

Compound / Brand name
Ianalumab (VAY736)
Partner
Novartis
Program

Ianalumab (VAY736) is an antibody directed against BAFF-R that is being investigated by Novartis in several indications including Sjögren’s syndrome, Autoimmune Hepatitis and Systemic Lupus Erythematosus (SLE). Ianalumab is currently in phase 2 clinical development and is expected to enter phase 3 clinical development in 2022 (Lupus Nephritis, Sjögren’s syndrome).

Compound / Brand name
Abelacimab (MAA868)
Partner
Anthos Therapeutics
Program

Abelacimab (MAA868) is an antibody directed against Factor XI that is being investigated by Anthos Therapeutics in a phase 3 clinical program for the prevention of venous thromboembolism (VTE) and cancer associated thrombosis (CAT).

Compound / Brand name
Felzartamab
Partner
HIBIO-I-Mab
Program

Felzartamab is a therapeutic human monoclonal antibody directed against CD38. Human Immunology Biosciences, Inc. (HIBio) obtained exclusive rights to develop and commercialize felzartamab across all indications worldwide, with the exception of Greater China. On behalf of HIBio, MorphoSys is evaluating felzartamab for patients with two renal autoimmune diseases, anti-PLA2R antibody-positive membranous nephropathy (M-PLACE and NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial). I-Mab Biopharma holds the exclusive regional rights to develop and commercialize felzartamab in Greater China and is studying felzartamab in relapsed/refractory multiple myeloma.

Compound / Brand name
Setrusumab (BPS804)
Partner
Mereo Biopharma and Ultragenyx
Program

Setrusumab (BPS804) is an antibody directed against sclerostin that is currently being investigated by Ultragenyx and Mereo Biopharma in a phase 2/3 clinical study for the treatment of osteogenesis imperfecta.

Compound / Brand name
NOV-8 (CMK389)
Partner
Novartis
Program

NOV-8 (CMK389) is being investigated by Novartis for the treatment of pulmonary sarcoidosis (Phase 2) and severe atopic dermatitis (also Phase 2).

Compound / Brand name
Bimagrumab
Partner
Novartis
Program

Bimagrumab is currently being investigated by Novartis and Versanis Bio in Phase 2 for the treatment of Type 2 diabetes.

Compound / Brand name
NOV-9 (LKA651)
Partner
Novartis
Program

NOV-9 (LKA651) is also currently being investigated by Novartis in Phase 2 for the treatment of diabetic eye diseases.

Compound / Brand name
NOV-14 (CSJ117)
Partner
Novartis
Program

NOV-14 (CSJ117) is currently under investigation by Novartis for the treatment of Asthma (Phase 2) and chronic obstructive pulmonary disease (COPD; also currently in Phase 2).

Compound / Brand name
MOR210
Partner
HIBIO-I-Mab
Program

MOR210 is a human antibody directed against C5aR1, the receptor of the complement factor C5a. Human Immunology Biosciences (HIBio) obtained exclusive worldwide rights to develop and commercialize MOR210 across all indications worldwide, with the exception of Greater China and South Korea. I-Mab Biopharma holds the exclusive rights for MOR210 in Greater China and South Korea and is currently investigating MOR210 for the treatment of relapsed or refractory advanced solid tumors (Phase 1).

Clinical Trials

Clinical Trials

Patients are kindly asked to contact their treating physicians if they are interested in participating in any of MorphoSys' clinical trials.

Clinical Trials